Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 56.77
- Piotroski Score 1.00
- Grade Buy
- Symbol (MNPR)
- Company Monopar Therapeutics Inc.
- Price $20.20
- Changes Percentage (2.5%)
- Change $0.49
- Day Low $19.54
- Day High $20.21
- Year High $38.50
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $29.50
- High Stock Price Target $37.00
- Low Stock Price Target $22.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.52
- Trailing P/E Ratio -1.56
- Forward P/E Ratio -1.56
- P/E Growth -1.56
- Net Income $-8,402,196
Income Statement
Quarterly
Annual
Latest News of MNPR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?
Monopar Therapeutics' stock (NASDAQ: MNPR) surged due to a licensing deal with Alexion for a promising drug to treat Wilson Disease. MNPR also showed positive results in its pipeline. The stock correc...
By Forbes | 3 weeks ago -
Monopar Therapeutics Inc. (MNPR) Stock Price, News, Quote & History - Yahoo Finance
Monopar Therapeutics has partnered with Alexion, AstraZeneca Rare Disease for the exclusive global license of ALXN-1840, a drug for Wilson disease. This agreement comes after successful Phase 3 trials...
By Yahoo! Finance | 4 weeks ago
